Name
|
Size
|
Creator |
Creation Date
|
Last Modification Date
|
Labels |
Attached To |
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Jun 08, 2016 13:54 |
Jun 08, 2016 13:56 |
|
Page: Cypress Quick Start Guide
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 22, 2015 13:53 |
Oct 22, 2015 13:54 |
|
Page: § 170.315 (d)(2) Auditable Events and Tamper-Resistance
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Scott Starkey |
Oct 22, 2015 13:53 |
Oct 22, 2015 13:54 |
|
Page: § 170.315 (a)(9) Clinical Decision Support
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 22, 2015 13:44 |
Oct 22, 2015 13:45 |
|
Page: § 170.315 (e)(1) View, Download, and Transmit to 3rd Party
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Scott Starkey |
Oct 22, 2015 13:44 |
Oct 22, 2015 13:45 |
|
Page: § 170.315 (a)(3) CPOE - Diagnostic Imaging
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Scott Starkey |
Oct 22, 2015 13:42 |
Oct 22, 2015 13:43 |
|
Page: § 170.315 (a)(2) CPOE - Laboratory
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 22, 2015 13:41 |
Oct 22, 2015 13:43 |
|
Page: § 170.315 (e)(2) Secure Messaging
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Scott Starkey |
Oct 22, 2015 13:49 |
Oct 22, 2015 13:50 |
|
Page: § 170.315 (a)(6) Problem List
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Scott Starkey |
Oct 22, 2015 13:48 |
Oct 22, 2015 13:49 |
|
Page: § 170.315 (a)(5) Demographics
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 22, 2015 13:47 |
Oct 22, 2015 13:49 |
|
Page: § 170.315 (d)(6) Emergency Access
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Scott Starkey |
Oct 22, 2015 13:47 |
Oct 22, 2015 13:48 |
|
Page: § 170.315 (a)(4) Drug-Drug, Drug-Allergy Interaction Checks for CPOE
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 27, 2015 18:53 |
Oct 27, 2015 18:54 |
|
Page: § 170.315 (f)(3) Transmission to Public Health Agencies - Reportable Laboratory Tests and Values/Results
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 27, 2015 18:49 |
Oct 27, 2015 18:50 |
|
Page: § 170.315 (f)(1) Transmission to Immunization Registries
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 27, 2015 18:49 |
Oct 27, 2015 18:52 |
|
Page: § 170.315 (f)(2) Transmission to Public Health Agencies - Syndromic Surveillance
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 28, 2015 16:55 |
Oct 28, 2015 16:55 |
|
Page: § 170.315 (a)(15) Social, Psychological, and Behavioral Determinants Data
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 28, 2015 16:54 |
Oct 28, 2015 16:54 |
|
Page: § 170.315 (a)(14) Implantable Device List
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 27, 2015 18:59 |
Oct 27, 2015 19:00 |
|
Page: § 170.315 (f)(6) Transmission to Public Health Agencies - Antimicrobial Use and Resistance Reporting
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 22, 2015 14:24 |
Oct 22, 2015 14:26 |
|
Page: § 170.315 (d)(8) Integrity
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 22, 2015 14:02 |
Oct 22, 2015 14:03 |
|
Page: § 170.315 (d)(1) Authentication, Access Control, Authorization
|
PDF File 170 314(a)(18)_ATLPublicComment_20141007_v2.pdf |
590 kB |
Christopher Watson |
Oct 23, 2015 17:10 |
Oct 23, 2015 17:11 |
|
Page: § 170.315 (d)(3) Audit Report(s)
|